Clinical trial
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
NCT00085540 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00085540 |
|---|---|
| Title | FR901228 in Treating Patients With Recurrent High-Grade Gliomas |
| Official title | A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor |
| Intervention type | Drug |
| Interventions | depsipeptide |
| Enrollment | 50 |
| Start date | Jan 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Jun 11, 2004 |
| Last update posted | Jan 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: